Drug Profile
ErythroMax
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator MaxCyte
- Class Inositol phosphates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypoxia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypoxia in USA (Extracorporeal)
- 15 Oct 2001 Phase-I clinical trials for Acute hypoxia in USA (Extracorporeal)
- 10 Sep 2001 Preclinical development for Acute hypoxia in USA (Extracorporeal)